Amarin Corp Plc (AMRN)

[MateoPaisa]

The brief takes no account whatsoever of the fact that intellectual property laws are being raped by those generics who want to do whatever the hell they want with the drug, even though the label may be very restrictive. The brief merely says that generics should have the right to use skinny labels and sell the drug for any and every purpose. They use *woe is the american public who has to pay higher prices for brand name drugs*

Stating a claim does not mean that a party has proven the claim in their favor, it merely means that there is enough in front of the judge to make her believe that there is a triable issue that should be given an opportunity to be proven in court. What is clear is that author of this brief is afraid that if this goes to court, their weak case will result in a loss.

The brief is an embarrassment to the generic industry